Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $1.90
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 30, 26 | Ascendiant Capital | maintain | Buy | Buy |
| Jun 11, 26 | Ascendiant Capital | maintain | Buy | Buy |
| Dec 10, 25 | Ascendiant Capital | maintain | Buy | Buy |
| Sep 25, 25 | Maxim Group | maintain | Buy | Buy |
| Sep 25, 25 | Ascendiant Capital | maintain | Buy | Buy |
| May 31, 23 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 21, 22 | HC Wainwright & Co. |
Daily · Wilder smoothing
| maintain |
| Buy |
| Buy |
| May 17, 22 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Apr 28, 22 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 36.71 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 9.52 | Oscillator | Buy |
| Williams %R (14) | -100.00 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.05 (Hist -0.01) | Oscillator | Strong Sell |
| Average Directional Index (14) | 22.80 (+DI 18.3 / -DI 16.7) | Trend | Buy |
| EMA 20 | 2.03 | MA | Strong Sell |
| SMA 20 | 2.03 | MA | Strong Sell |
| EMA 50 | 2.11 | MA | Strong Sell |
| SMA 50 | 2.14 | MA | Strong Sell |
| SMA 200 | 2.34 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | AYTU | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.4x | -0.9x · sector 20.7x | Discount |
| Forward P/E (FY27E) | -3.0x | EPS est. -0.62 | Elevated |
| Price / Book | 0.7x | 0.5x | Elevated |
| Price / Sales | 0.4x | 0.2x | Elevated |
| EV / EBITDA | -1.5x | -0.3x | Elevated |
| Return on equity | -52.9% | — | Weak |
| Gross margin | 64.0% | 64.5% | In line |
| Debt / Equity | 0.51 | 0.70 | Moderate |
| Piotroski / Altman Z | 4/9 | Z -4.21 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jul 28, 26 | Disbrow Joshua R. | director, officer: Chief Executive Officer | A-Award | 30,000 | — |
| Jul 28, 26 | Pyszczymuka Greg | officer: Chief Commercial Officer | A-Award | 20,000 | — |
| Jul 28, 26 | Disbrow Jarrett | officer: Chief Business Officer | A-Award | 15,000 | — |
| Jul 28, 26 | Selhorn Ryan J | officer: Chief Financial Officer | A-Award | 25,000 | — |
| Jul 28, 26 | Liu Vivian H | director | A-Award | 10,000 | — |
| Jul 28, 26 | Jain Abhinav | director | A-Award | 10,000 | — |
| Jul 28, 26 | Dockery Carl | director | A-Award | 10,000 | — |
| Jul 28, 26 | Donofrio John Jr. | director | A-Award | 10,000 | — |
Stock news · updated daily
ELTP and AYTU have different CNS portfolios, growth drivers and valuations, but which pharmaceutical stock looks better positioned? Let's dive in.
Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago.
Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 million EXXUA net revenue of $6.6 million in fiscal 2026, including $3.9 million in the fourth quarter, following full commercial launch during third quarter fiscal 2026 EXXUA fourth quarter fiscal 2026 total prescriptions were 3,323, up approximately 138% from 1,398 in third quarter fiscal 2026 $26.3 million cash balance at June 30, 2026 Company to host conference call and webcast today, September 22, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / September 22, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 full year and fourth quarter.
DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, September 22, 2026, at 4:30 p.m.
AWM Investment Company Inc. bought a new stake in Aytu BioPharma Inc. (NASDAQ: AYTU) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 619,574 shares of the company's stock, valued at approximately $1,332,000. AWM Investment Company Inc. owned
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Sep 22, 2026 | -0.29 | -0.05 | Beat 82.8% | $16.11M |
| May 13, 2026 | -0.31 | -0.53 | Miss -71.0% | $12.41M |
| Feb 3, 2026 | -0.26 | -1.05 | Miss -303.8% | $15.20M |
| Nov 13, 2025 | -0.06 | -0.08 | Miss -33.3% | $13.89M |
| Sep 23, 2025 | -0.02 | -2.92 | Miss -14500.0% | $15.13M |
| May 14, 2025 | -0.17 | 0.20 | Beat 217.6% | $18.45M |
FY2024 · 10-K disclosure
FY2024 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| DEF 14A | Oct 22, 2026 | 2026-10-22 16:30:24 | View |
| 10-K | Sep 22, 2026 | 2026-09-22 16:14:36 | View |
| 8-K | Sep 22, 2026 | 2026-09-22 16:05:55 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 12:08:31 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:34:20 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:34:01 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:33:43 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:33:22 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:32:12 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:31:51 | View |
Proxy statement (DEF 14A) disclosures
